ProVac: Promotion of Evidence-Based Decision Making on New Vaccine Introductions
The ProVac Initiative was initially developed by the Pan American Health Organization (PAHO) in response to Latin American country requests for technical support in the integration of economic analyses in decisions on new vaccine introductions (e.g., rotavirus, pneumococcal conjugate, Haemophilus influenzae type b). The main goal of the ProVac Initiative is to promote and strengthen evidence-based immunization policies.
ProVac IWG: Extension to the AFRO, EMRO, and EURO Regions
Following the request of several partners and countries outside the Americas, PAHO decided to implement ProVac to other WHO regions, and created an International Working Group (IWG) for this purpose. The ProVac IWG aims to transfer tools, methods, and lessons learned from ProVac in AFRO (Africa), EMRO (Eastern Mediterranean), and EURO (Europe) to promote evidence-based policies regarding new vaccine introductions. Partners involved in the IWG include AMP, PAHO, PATH, Sabin Institute, the U.S. Centers for Disease Prevention and Control (CDC), and WHO headquarters. The project is funded by the Bill & Melinda Gates Foundation.
AMP Provides Direct Technical Assistance to EURO and EMRO Countries
The role of AMP, in collaboration with WHO regional offices, is to provide direct technical assistance to country teams in four EURO countries (Albania, Azerbaijan, Croatia, Georgia) and two EMRO countries (Egypt and Iran) using ProVac tools and methodologies. More specifically, AMP helps country teams to conduct cost-effectiveness analysis using the TRIVAC model in order to provide evidence for decision making in immunization. Additionally, in collaboration with WHO, AMP organizes two regional workshops in EURO and AFRO to share ProVac tools and to support evidence-based decision making.
|ProVac IWG brochure.pdf||481.73 KB|